Endo International plc – Ordinary Shares (NASDAQ:ENDP) announced that one of its operating companies, Par Pharmaceutical, has begun shipping mycophenolate mofetil hydrochloride (HCl) for injection following final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application. Par’s mycophenolate mofetil hydrochloride (HCl) for injection is the generic version of Roche’s CellCept® and is the first and currently the only generic injectable available. According to IMS Health data, U.S. sales of injectable CellCept® were approximately $42 million for the 12 months ended October 31, 2016.
Mycophenolate mofetil hydrochloride (HCl) for injection is packaged in cartons of four 500 mg single dose vials.
CellCept® is a registered trademark of Hoffman-LaRoche Inc. (Original Source)
Shares of Endo are currently trading at $15.76, down $0.11 or -0.69%. ENDP has a 1-year high of $63.63 and a 1-year low of $12.56. The stock’s 50-day moving average is $19.67 and its 200-day moving average is $18.92.
On the ratings front, ENDP stock has been the subject of a number of recent research reports. In a report issued on November 21, JMP analyst Donald Ellis reiterated a Buy rating on ENDP, with a price target of $34, which implies an upside of 114% from current levels. Separately, on November 11, Mizuho’s Irina Rivkind Koffler reiterated a Buy rating on the stock and has a price target of $25.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Donald Ellis and Irina Rivkind Koffler have a yearly average return of 17.7% and 15.3% respectively. Ellis has a success rate of 59% and is ranked #689 out of 4256 analysts, while Koffler has a success rate of 48% and is ranked #106.
Overall, 6 research analysts have assigned a Hold rating and 4 research analysts have given a Buy rating to the stock. When considering if perhaps the stock is under or overvalued, the average price target is $28.67 which is 81% above where the stock closed yesterday.
Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. It operates through the following segments U.S. Branded Pharmaceuticals, U.S. Generic pharmaceuticals, Devices, and International Pharmaceuticals. The U.S. Branded Pharmaceuticals offers products that focus on the treatment and management of conditions in urology, urologic oncology, endocrinology, and orthopedics. The U.S. Generic pharmaceuticals segment consist of a differentiated product portfolio including high-barrier-to-entry products, first-to-file or first-to-market opportunities that are difficult to formulate, difficult to manufacture or face complex legal and regulatory challenges. The Devices segment offers medical devices that deliver innovative medical technology solutions to physicians treating female incontinence and pelvic floor repair. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets.